RTW backs Umoja Biopharma – Umoja Biopharma, Inc. has just completed a $210m Series B financing round. RTW Venture Fund participated in the financing round together with other investment firms, including other investment vehicles of RTW Investments, LP.
Umoja is a US-based privately held oncology company. It is using a new approach to immunotherapy, reprogramming immune cells directly in the human body to create next-generation immunotherapies for the treatment of solid tumors and haematologic malignancies. Umoja intends to use the proceeds from this financing round to expand its integrated technologies, advance its product candidates based on on CAR T-cell adapter-mediated tumor-targeting platform (TumorTag) and in vivo vector delivery and cell expansion platforms (VivoVec and RACR) through preclinical and into clinical development, and build internal manufacturing capabilities to support clinical development of its pipeline programmes.
The Series B financing was co-led by SoftBank Vision Fund 2 and Cormorant Asset Management.
The company raised $53m in its Series A financing in November 2020.